ARTICLE | Finance

Buyside view XXIII: Milestones galore

2015 sees investors focus on big launches, cancer combos, NASH and gene therapy

January 12, 2015 8:00 AM UTC

Buyside view XXIII

The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches in 2015, but only a handful of approvals...